The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy

被引：0

作者：

Fujita, Kazutoshi ^{[1
]}

Matsushita, Yuto ^{[2
]}

Toyoda, Shingo ^{[1
]}

Kojima, Takahiro ^{[3
]}

Yamashita, Shimpei ^{[4
]}

Taniguchi, Hisanori ^{[5
]}

Monji, Keisuke ^{[6
]}

Ishiyama, Ryo ^{[7
]}

Tatarano, Shuichi ^{[8
]}

Masui, Kimihiko ^{[9
]}

Nakamura, Eijiro ^{[10
]}

Kaneko, Tomoyuki ^{[11
]}

Kitano, Goshi ^{[3
]}

Motoshima, Takanobu ^{[12
]}

Shiraishi ^{[13
]}

Kira, Satoru ^{[13
]}

Murashima, Takaya ^{[14
]}

Hara, Hiroaki ^{[15
]}

Matsumura ^{[16
]}

Nishiyama, Naotaka ^{[17
]}

Miyake, Hideaki ^{[2
]}

Kitamura, Hiroshi ^{[1
]}

Uemura, Hirotsugu ^{[1
]}

机构：

[1] Kindai Univ, Fac Med, Dept Urol, Osakasayama, Japan

[2] Hamamatsu Univ Sch Med, Dept Urol, Hamamatsu, Shizuoka, Japan

[3] Aichi Canc Ctr, Dept Urol, Nagoya, Japan

[4] Wakayama Med Univ, Dept Urol, Wakayama, Japan

[5] Kansai Med Univ, Dept Urol & Androl, Hirakata, Japan

[6] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan

[7] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan

[8] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Urol, Kagoshima, Japan

[9] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan

[10] Natl Canc Ctr, Dept Urol, Tokyo, Japan

[11] Teikyo Univ, Sch Med, Dept Urol, Tokyo, Japan

[12] Kumamoto Univ, Grad Sch Med Sci, Dept Urol, Kumamoto, Japan

[13] Univ Yamanashi, Dept Urol, Grad Sch Med Sci, Yamanashi, Japan

[14] Miyazaki Univ, Fac Med, Dept Urol, Miyazaki, Japan

[15] Shinshu Univ, Dept Urol, Matsumoto, Japan

[16] Natl Hosp Org Shikoku Canc Ctr, Dept Urol, Ehime, Japan

[17] Univ Toyama, Fac Med, Dept Urol, Toyama, Japan

来源：

WORLD JOURNAL OF UROLOGY | 2024年 / 42卷 / 01期

关键词：

Non-clear cell renal cell carcinoma; Tyrosine-kinase inhibitor; Ipilimumab-nivolumab; 2nd line therapy; SUNITINIB; PHASE-2;

D O I：

10.1007/s00345-024-05252-2

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

PurposeMetastatic non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous disease with a poor prognosis and is treated with immunotherapy (IO)-based combinations according to the clear cell renal cell carcinoma. Tyrosine-kinase inhibitors (TKIs), such as cabozantinib and axitinib, are commonly used as the 2nd line therapy after 1st line IO combination therapy, but their efficacy as 2nd line TKI therapy for nccRCC is unknown. In this study, we performed a retrospective multicenter analysis of nccRCC patients who were previously treated with IO combination therapy and received 2nd line TKIs.MethodsAmong 254 patients enrolled in the Japanese multicenter retrospective study, 52 patients with nccRCC histology who received second-line TKIs were included in this study. Progression-free survival and overall survival (OS) from 2nd line TKIs were analyzed by log-rank test and Cox-proportional hazard model. Objective response rate (ORR) of 2nd line TKIs were analyzed.ResultsThe 1-year PFS and OS rates were 25.0% (95% CI = 13.1-36.8) and 63.8% (95% CI, 48.0-75.9), respectively. No patients had a complete response, 11 had a partial response, and 18 had stable disease. ORR was 21.1%. IMDC poor risk and sunitinib as the 2nd line therapy were significantly associated with poor PFS.ConclusionThe 2nd-line TKI was effective for a small group of nccRCC patients previously treated with IO combination therapy, although this study was retrospectively analyzed with a small number of cases.

引用

页数：8

共 17 条

[1] Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61) a single-arm, multicentre, phase 2 trial [J].

Albiges, Laurence ;

Gurney, Howard ;

Atduev, Vagif ;

Suarez, Cristina ;

Climent, Miguel A. ;

Pook, David ;

Tomczak, Piotr ;

Barthelemy, Philippe ;

Lee, Jae Lyun ;

Stus, Viktor ;

Ferguson, Thomas ;

Wiechno, Pawel ;

Gokmen, Erhan ;

Lacombe, Louis ;

Gedye, Craig ;

Perini, Rodolfo F. ;

Sharma, Manish ;

Peng, Xiang ;

Lee, Chung-Han .

LANCET ONCOLOGY, 2023, 24 (08) :881-891

[2] Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial [J].

Armstrong, Andrew J. ;

Halabi, Susan ;

Eisen, Tim ;

Broderick, Samuel ;

Stadler, Walter M. ;

Jones, Robert J. ;

Garcia, Jorge A. ;

Vaishampayan, Ulka N. ;

Picus, Joel ;

Hawkins, Robert E. ;

Hainsworth, John D. ;

Kollmannsberger, Christian K. ;

Logan, Theodore F. ;

Puzanov, Igor ;

Pickering, Lisa M. ;

Ryan, Christopher W. ;

Protheroe, Andrew ;

Lusk, Christine M. ;

Oberg, Sadie ;

George, Daniel J. .

LANCET ONCOLOGY, 2016, 17 (03) :378-388

[3] Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib The SURTIME Randomized Clinical Trial [J].

Bex, Axel ;

Mulders, Peter ;

Jewett, Michael ;

Wagstaff, John ;

van Thienen, Johannes V. ;

Blank, Christian U. ;

van Velthoven, Roland ;

Laguna, Maria del Pilar ;

Wood, Lori ;

van Melick, Harm H. E. ;

Aarts, Maureen J. ;

Lattouf, J. B. ;

Powles, Thomas ;

de Jong, Igle Jan ;

Rottey, Sylvie ;

Tombal, Bertrand ;

Marreaud, Sandrine ;

Collette, Sandra ;

Collette, Laurence ;

Haanen, John .

JAMA ONCOLOGY, 2019, 5 (02) :164-170

[4] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial [J].

Choueiri, Toni K. ;

Halabi, Susan ;

Sanford, Ben L. ;

Hahn, Olwen ;

Michaelson, M. Dror ;

Walsh, Meghara K. ;

Feldman, Darren R. ;

Olencki, Thomas ;

Picus, Joel ;

Small, Eric J. ;

Dakhil, Shaker ;

George, Daniel J. ;

Morris, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) :591-+

[5] Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations [J].

Fitzgerald, Kelly N. ;

Duzgol, Cihan ;

Knezevic, Andrea ;

Shapnik, Natalie ;

Kotecha, Ritesh ;

Aggen, David H. ;

Carlo, Maria I. ;

Shah, Neil J. ;

Voss, Martin H. ;

Feldman, Darren R. ;

Motzer, Robert J. ;

Lee, Chung -Han .

EUROPEAN UROLOGY, 2023, 83 (03) :195-199

[6] Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study [J].

Huang, Tingxuan ;

Wang, Jun ;

Liu, Ruiqi ;

Wei, Wensu ;

Liu, Yang ;

Zhang, Zhiling ;

Guo, Shengjie ;

Han, Hui ;

Zhou, Fangjian ;

He, Liru ;

Dong, Pei .

CLINICAL GENITOURINARY CANCER, 2024, 22 (02) :252-260.e3

[7] Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma [J].

Mahoney, Kathleen M. ;

Jacobus, Susanna ;

Bhatt, Rupal S. ;

Song, Jiaxi ;

Carvo, Ingrid ;

Cheng, Su-Chun ;

Simpson, Mekailah ;

Fay, Andre P. ;

Puzanov, Igor ;

Michaelson, M. Dror ;

Atkins, Michael B. ;

McDermott, David F. ;

Signoretti, Sabina ;

Choueiri, Toni K. .

CLINICAL GENITOURINARY CANCER, 2016, 14 (04) :304-+

[8] Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma [J].

Mejean, A. ;

Ravaud, A. ;

Thezenas, S. ;

Colas, S. ;

Beauval, J. -B. ;

Bensalah, K. ;

Geoffrois, L. ;

Thiery-Vuillemin, A. ;

Cormier, L. ;

Lang, H. ;

Guy, L. ;

Gravis, G. ;

Rolland, F. ;

Linassier, C. ;

Lechevallier, E. ;

Beisland, C. ;

Aitchison, M. ;

Oudard, S. ;

Patard, J. -J. ;

Theodore, C. ;

Chevreau, C. ;

Laguerre, B. ;

Hubert, J. ;

Gross-Goupil, M. ;

Bernhard, J. -C. ;

Albiges, L. ;

Timsit, M. -O. ;

Lebret, T. ;

Escudier, B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (05) :417-427

[9] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) long-term follow-up results from an open-label, randomised, phase 3 trial [J].

Motzer, Robert J. ;

Powles, Thomas ;

Burotto, Mauricio ;

Escudier, Bernard ;

Bourlon, Maria T. ;

Shah, Amishi Y. ;

Suarez, Cristina ;

Hamzaj, Alketa ;

Porta, Camillo ;

Hocking, Christopher M. ;

Kessler, Elizabeth R. ;

Gurney, Howard ;

Tomita, Yoshihiko ;

Bedke, Jens ;

Zhang, Joshua ;

Simsek, Burcin ;

Scheffold, Christian ;

Apolo, Andrea B. ;

Choueiri, Toni K. .

LANCET ONCOLOGY, 2022, 23 (07) :888-898

[10] Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Cella, David ;

Reeves, James ;

Hawkins, Robert ;

Guo, Jun ;

Nathan, Paul ;

Staehler, Michael ;

de Souza, Paul ;

Merchan, Jaime R. ;

Boleti, Ekaterini ;

Fife, Kate ;

Jin, Jie ;

Jones, Robert ;

Uemura, Hirotsugu ;

De Giorgi, Ugo ;

Harmenberg, Ulrika ;

Wang, Jinwan ;

Sternberg, Cora N. ;

Deen, Keith ;

McCann, Lauren ;

Hackshaw, Michelle D. ;

Crescenzo, Rocco ;

Pandite, Lini N. ;

Choueiri, Toni K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08) :722-731

← 1 2 →